BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Butti R, Nimma R, Kundu G, Bulbule A, Kumar TVS, Gunasekaran VP, Tomar D, Kumar D, Mane A, Gill SS, Patil T, Weber GF, Kundu GC. Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression. Oncogene 2021;40:2002-17. [PMID: 33603163 DOI: 10.1038/s41388-021-01663-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun J, Yang M, Zhao W, Wang F, Yang L, Tan C, Hu T, Zhu H, Zhao G. Research progress on the relationship between the TOR signaling pathway regulator, epigenetics, and tumor development. Front Genet 2022;13:1006936. [DOI: 10.3389/fgene.2022.1006936] [Reference Citation Analysis]
2 Pan S, Li S, Zhan Y, Chen X, Sun M, Liu X, Wu B, Li Z, Liu B. Immune status for monitoring and treatment of bladder cancer. Front Immunol 2022;13:963877. [DOI: 10.3389/fimmu.2022.963877] [Reference Citation Analysis]
3 Tan Y, Zhao L, Yang Y, Liu W. The Role of Osteopontin in Tumor Progression Through Tumor-Associated Macrophages. Front Oncol 2022;12:953283. [DOI: 10.3389/fonc.2022.953283] [Reference Citation Analysis]
4 Hu D, Li Z, Zheng B, Lin X, Pan Y, Gong P, Zhuo W, Hu Y, Chen C, Chen L, Zhou J, Wang L. Cancer-associated fibroblasts in breast cancer: Challenges and opportunities. Cancer Commun (Lond) 2022. [PMID: 35481621 DOI: 10.1002/cac2.12291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zeltz C, Navab R, Heljasvaara R, Kusche-Gullberg M, Lu N, Tsao MS, Gullberg D. Integrin α11β1 in tumor fibrosis: more than just another cancer-associated fibroblast biomarker? J Cell Commun Signal 2022. [PMID: 35378690 DOI: 10.1007/s12079-022-00673-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Radharani NNV, Yadav AS, Nimma R, Kumar TVS, Bulbule A, Chanukuppa V, Kumar D, Patnaik S, Rapole S, Kundu GC. Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway. Cancer Cell Int 2022;22:122. [PMID: 35300689 DOI: 10.1186/s12935-022-02527-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Tinsley SL, Allen-Petersen BL. PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen. NAR Cancer 2022;4:zcac002. [PMID: 35118387 DOI: 10.1093/narcan/zcac002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Watson KL, Yi R, Moorehead RA. Transgenic overexpression of the miR-200b/200a/429 cluster inhibits mammary tumor initiation. Transl Oncol 2021;14:101228. [PMID: 34562686 DOI: 10.1016/j.tranon.2021.101228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Porwal A, Kundu GC, Bhagwat G, Butti R. Polyherbal formulation Anoac‑H suppresses the expression of RANTES and VEGF for the management of bleeding hemorrhoids and fistula. Mol Med Rep 2021;24:736. [PMID: 34414451 DOI: 10.3892/mmr.2021.12376] [Reference Citation Analysis]
10 Pereira JFS, Jordan P, Matos P. A Signaling View into the Inflammatory Tumor Microenvironment. Immuno 2021;1:91-118. [DOI: 10.3390/immuno1020007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]